NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.


Por: Bourhis, J, Auperin, A, Borel, C, Lefebvre, G, Racadot, S, Geoffrois, L, Sun, XS, Saada, E, Cirauqui, B, Rutkowski, T, Henry, S, Modesto, A, Johnson, A, Calderon, B, Pointreau, Y, Ruiz, EP, Kazmierska, J, Psyrri, A, Mesia, R and Tao, YA

Publicada: 10 jun 2025
Resumen:


Filiaciones:
Batiment Hosp, CHUV, Lausanne, Switzerland
Gustave Roussy, Villejuif, France
Inst Cancerol Strasbourg Europe, Strasbourg, France
Ctr Oscar Lambret, Lille, France
Ctr Leon Berard, Lyon, France
Inst Cancerol Lorraine, Med Oncol Dept, Nancy, France
Hop Nord Franche Comte, Montbelliard, France
Ctr Antoine Lacassagne, Nice, France
Inst Catala Oncol Badalona, Barcelona, Spain
Maria Sklodowska Curie Inst Oncol, Gliwice, Poland
BGOG, Namur, Belgium
CHU UCL Namur Site Sainte Elisabeth, Namur, Belgium
Claudius Regaud Inst, Toulouse, France
Ctr Francois Baclesse, Caen, France
Inst St Catherine, Avignon, France
Ctr Jean Bernard, Le Mans, France
Univ Malaga, Hosp Reg, Malaga, Spain
Greater Poland Canc Ctr, Poznan, Poland
Attikon Univ Hosp, Sect Med Oncol, Athens, Greece
IGTP, B ARGO Grp, Inst Catala Oncol Badalona, Badalona, Spain
ISSN: 0732183X





JOURNAL OF CLINICAL ONCOLOGY
Editorial
American Society of Clinical Oncology, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA, Estados Unidos America
Tipo de documento: Meeting Abstract
Volumen: 43 Número: 17_SUPPL
Páginas: 2-2
WOS Id: 001511777200001

MÉTRICAS